Life Expectancy News and Research

RSS

Life expectancy is the expected (in the statistical sense) number of years of life remaining at a given age. It is denoted by e''x'', which means the average number of subsequent years of life for someone now aged ''x'', according to a particular mortality experience.

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

10 Dec 2010

European researchers develop new form of therapy for Alpha-mannosidosis

Alpha-mannosidosis is a rare childhood disease which causes symptoms such as mental retardation or hearing loss and is linked to a lower life expectancy. A European research team headed by Professor Paul Saftig from Christian-Albrechts-Universit-t zu Kiel has developed a form of therapy as part of the Alpha-Man project, which will receive around six million euros from the European Union for its next stage of trials.

9 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria who were treated long-term with Soliris (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando.

7 Dec 2010

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

KIRN 670AM RADIOIRAN to create new awareness about prostate cancer

KIRN 670AM RADIOIRAN has been serving the Iranian-American/Persian population of Los Angeles for more than a decade. During the past year, John Paley, VP and General Manager of KIRN, organized a series of interactive informational broadcasts about breast and esophageal cancer. Teams of medical experts in these fields thoroughly reviewed signs, treatment, myths and realities about this implacable disease.

4 Dec 2010

Columbia's professor receives 2010 Garfield Economic Impact Award

The 2010 Garfield Economic Impact Award was presented today to Frank R. Lichtenberg, PhD, of Columbia Business School. Research!America has presented this award since 2002, to recognize the outstanding work of economists who demonstrate how medical and health research impacts the economy. The award is supported by a grant from Merck & Co., Inc., and by the Eugene Garfield Foundation.

3 Dec 2010

Impairments to health and physical performance are due to unfavorable lifestyle habits and lack of exercise

Impairments to health and physical performance are not primarily a result of aging but of unfavorable lifestyle habits and lack of exercise. This is the position taken by Dieter Leyk and his coauthors in the new issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[46]: 809-16).

2 Dec 2010

U.S. retirees need hundreds of thousands to pay for medical expenses, report finds

Some medical costs have fallen this year thanks to new health care reform laws, but U.S. retirees will still need hundreds of thousands of dollars in savings to cover their lifetime medical expenses.

1 Dec 2010

Older adults with diabetes have reduced life expectancy

Despite medical advances enabling those with diabetes to live longer today than in the past, a 50-year-old with the disease still can expect to live 8.5 years fewer years, on average, than a 50-year-old without the disease.

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Flawed health care system fuels low life expectancy rank for U.S., researchers say

The U.S. spends more on health care than any other nation but ranks 49th in life expectancy which has led researchers to conclude that the problem is the health care system.

1 Dec 2010

Queenslanders fatter but live longer and smoke less: Health report

A new health report reveals that more than 60 per cent of Queensland adults are overweight or obese. The Health of Queenslanders report also reveals that Queenslanders are living longer and smoking less.

29 Nov 2010

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

Researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ), following 10 years of studying tobacco use among smokers with mental illness, have developed a comprehensive strategy for recovery from smoking addiction that could serve as a nationwide model.

25 Nov 2010

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.

18 Nov 2010

Urgent action needed to address urban health inequities

A new report published today by WHO and the United Nations Human Settlements Programme (UN-HABITAT) shows for the first time how ill-health is linked to poverty in cities, and not just among the poorest urban populations. It calls for policymakers to take action targeting health inequities.

18 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.

16 Nov 2010

Life Expectancy News and Research

Further Reading

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

European researchers develop new form of therapy for Alpha-mannosidosis

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

First patient dosed with rFVIIIFc in A-LONG trial

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

KIRN 670AM RADIOIRAN to create new awareness about prostate cancer

Columbia's professor receives 2010 Garfield Economic Impact Award

Impairments to health and physical performance are due to unfavorable lifestyle habits and lack of exercise

U.S. retirees need hundreds of thousands to pay for medical expenses, report finds

Older adults with diabetes have reduced life expectancy

Active surveillance improves quality of life in low-risk prostate cancer patients

Flawed health care system fuels low life expectancy rank for U.S., researchers say

Queenslanders fatter but live longer and smoke less: Health report

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

Urgent action needed to address urban health inequities

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News